{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:37:21Z","timestamp":1788363441307,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T00:00:00Z","timestamp":1360886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00280-013-2094-0","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T06:46:22Z","timestamp":1360824382000},"page":"999-1011","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter"],"prefix":"10.1007","volume":"71","author":[{"given":"Christina","family":"Cherian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Kugel Desmoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Polin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juiwanna","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleem","family":"Gangjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry H.","family":"Matherly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,15]]},"reference":[{"key":"2094_CR1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0021-9258(17)31261-9","volume":"264","author":"GP Beardsley","year":"1989","unstructured":"Beardsley GP, Moroson BA, Taylor EC, Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328\u2013333","journal-title":"J Biol Chem"},{"key":"2094_CR2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","volume":"6","author":"S Chattopadhyay","year":"2007","unstructured":"Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404\u2013417","journal-title":"Mol Cancer Ther"},{"key":"2094_CR3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1005875015011","volume":"15","author":"TH Corbett","year":"1997","unstructured":"Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, Pugh S, White K, Kushner J, Rake J, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, Moore R (1997) Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs 15:207\u2013218","journal-title":"Invest New Drugs"},{"key":"2094_CR4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1378\/chest.125.3.1103","volume":"125","author":"DW Cugell","year":"2004","unstructured":"Cugell DW, Kamp DW (2004) Asbestos and the pleura: a review. Chest 125:1103\u20131117","journal-title":"Chest"},{"key":"2094_CR5","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1021\/jm8003366","volume":"51","author":"Y Deng","year":"2008","unstructured":"Deng Y, Wang Y, Cherian C, Hou Z, Buck SA, Matherly LH, Gangjee A (2008) Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. J Med Chem 51:5052\u20135063","journal-title":"J Med Chem"},{"key":"2094_CR6","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/jm8011323","volume":"52","author":"Y Deng","year":"2009","unstructured":"Deng Y, Zhou X, Kugel Desmoulin S, Wu J, Cherian C, Hou Z, Matherly LH, Gangjee A (2009) Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. J Med Chem 52:2940\u20132951","journal-title":"J Med Chem"},{"key":"2094_CR7","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1016\/S0021-9258(17)42956-5","volume":"259","author":"G Fabre","year":"1984","unstructured":"Fabre G, Fabre I, Matherly LH, Cano JP, Goldman ID (1984) Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro. J Biol Chem 259:5066\u20135072","journal-title":"J Biol Chem"},{"key":"2094_CR8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","volume":"5","author":"DA Fennell","year":"2008","unstructured":"Fennell DA, Gaudino G, O\u2019Byrne KJ, Mutti L, van Meerbeeck J (2008) Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5:136\u2013147","journal-title":"Nat Clin Pract Oncol"},{"key":"2094_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11864-011-0152-6","volume":"12","author":"LL Garland","year":"2011","unstructured":"Garland LL (2011) Chemotherapy for malignant pleural mesothelioma. Curr Treat Options Oncol 12:181\u2013188","journal-title":"Curr Treat Options Oncol"},{"key":"2094_CR10","doi-asserted-by":"crossref","first-page":"11721","DOI":"10.1158\/0008-5472.CAN-05-2034","volume":"65","author":"DD Gibbs","year":"2005","unstructured":"Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL (2005) BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 65:11721\u201311728","journal-title":"Cancer Res"},{"key":"2094_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0163-7258(85)90083-X","volume":"28","author":"ID Goldman","year":"1985","unstructured":"Goldman ID, Matherly LH (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 28:77\u2013102","journal-title":"Pharmacol Ther"},{"key":"2094_CR12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","volume":"9","author":"M Hazarika","year":"2004","unstructured":"Hazarika M, White RM, Johnson JR, Pazdur R (2004) FDA drug approval summaries: pemetrexed (Alimta). Oncologist 9:482\u2013488","journal-title":"Oncologist"},{"key":"2094_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm0297-177","volume":"3","author":"G Helmlinger","year":"1997","unstructured":"Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3:177\u2013182","journal-title":"Nat Med"},{"key":"2094_CR14","first-page":"507","volume":"6","author":"GB Henderson","year":"1983","unstructured":"Henderson GB, Zevely EM (1983) Use of non-physiological buffer systems in the analysis of methotrexate transport in L1210 cells. Biochem Int 6:507\u2013515","journal-title":"Biochem Int"},{"key":"2094_CR15","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1074\/jbc.M111.306860","volume":"287","author":"Z Hou","year":"2011","unstructured":"Hou Z, Kugel Desmoulin S, Etnyre E, Olive M, Hsiung B, Cherian C, Wloszczynski PA, Moin K, Matherly LH (2011) Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. J Biol Chem 287:4982\u20134995","journal-title":"J Biol Chem"},{"key":"2094_CR16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107327480601300402","volume":"13","author":"R Ismail-Khan","year":"2006","unstructured":"Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR (2006) Malignant pleural mesothelioma: a comprehensive review. Cancer Control 13:255\u2013263","journal-title":"Cancer Control"},{"key":"2094_CR17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4161\/cbt.22020","volume":"13","author":"S Kugel Desmoulin","year":"2012","unstructured":"Kugel Desmoulin S, Hou Z, Gangjee A, Matherly LH (2012) The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol Ther 13:1355\u20131373","journal-title":"Cancer Biol Ther"},{"key":"2094_CR18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1124\/mol.111.073833","volume":"80","author":"S Kugel Desmoulin","year":"2011","unstructured":"Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH (2011) Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol 80:1096\u20131107","journal-title":"Mol Pharmacol"},{"key":"2094_CR19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/mol.112.079004","volume":"82","author":"S Kugel Desmoulin","year":"2012","unstructured":"Kugel Desmoulin S, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH (2012) Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Mol Pharmacol 82:591\u2013600","journal-title":"Mol Pharmacol"},{"key":"2094_CR20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/mol.110.065896","volume":"78","author":"S Kugel Desmoulin","year":"2010","unstructured":"Kugel Desmoulin S, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, Chang MH, Romero MF, Cherian C, Gangjee A, Matherly LH (2010) Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol 78:577\u2013587","journal-title":"Mol Pharmacol"},{"key":"2094_CR21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265\u2013275","journal-title":"J Biol Chem"},{"key":"2094_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10555-007-9046-2","volume":"26","author":"LH Matherly","year":"2007","unstructured":"Matherly LH, Hou Z, Deng Y (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26:111\u2013128","journal-title":"Cancer Metastasis Rev"},{"key":"2094_CR23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjc.6605501","volume":"102","author":"JE Nutt","year":"2010","unstructured":"Nutt JE, Razak AR, O\u2019Toole K, Black F, Quinn AE, Calvert AH, Plummer ER, Lunec J (2010) The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer 102:553\u2013560","journal-title":"Br J Cancer"},{"key":"2094_CR24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0003-4975(95)00045-M","volume":"59","author":"HI Pass","year":"1995","unstructured":"Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, Mew DJ, Pogrebniak HW, Matthews WJ (1995) Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 59:835\u2013844","journal-title":"Ann Thorac Surg"},{"key":"2094_CR25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-60761-968-0_3","volume-title":"Transplantable syngeneic tumors: solid tumors of mice. Tumor models in cancer research","author":"LCT Polin","year":"2011","unstructured":"Polin LCT, Roberts BJ, Lawson AJ, Leopold WR III, White K, Kusner J, Paluch J, Hazeldine S, Moore R, Rake J, Horwitz JP (2011) Transplantable syngeneic tumors: solid tumors of mice. Tumor models in cancer research. Humana Press, Inc., Totowa, NJ, pp 43\u201378"},{"key":"2094_CR26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1005856605726","volume":"15","author":"L Polin","year":"1997","unstructured":"Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Peltier N, Golakoti T, Patterson G, Moore R, Corbett TH (1997) Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs 15:99\u2013108","journal-title":"Invest New Drugs"},{"key":"2094_CR27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1014469828729","volume":"20","author":"L Polin","year":"2002","unstructured":"Polin L, White K, Kushner J, Paluch J, Simpson C, Pugh S, Edelstein MK, Hazeldine S, Fontana J, LoRusso P, Horwitz JP, Corbett TH (2002) Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. Invest New Drugs 20:13\u201322","journal-title":"Invest New Drugs"},{"key":"2094_CR28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cell.2006.09.041","volume":"127","author":"A Qiu","year":"2006","unstructured":"Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917\u2013928","journal-title":"Cell"},{"key":"2094_CR29","doi-asserted-by":"crossref","first-page":"C1669","DOI":"10.1152\/ajpcell.00202.2007","volume":"293","author":"A Qiu","year":"2007","unstructured":"Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, Goldman ID (2007) Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol 293:C1669\u2013C1678","journal-title":"Am J Physiol Cell Physiol"},{"key":"2094_CR30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0006-2952(98)00306-2","volume":"57","author":"N Raghunand","year":"1999","unstructured":"Raghunand N, Altbach MI, van Sluis R, Baggett B, Taylor CW, Bhujwalla ZM, Gillies RJ (1999) Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol 57:309\u2013312","journal-title":"Biochem Pharmacol"},{"key":"2094_CR31","first-page":"3675","volume":"61","author":"CL Wilt van der","year":"2001","unstructured":"van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ (2001) Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 61:3675\u20133681","journal-title":"Cancer Res"},{"key":"2094_CR32","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/jn\/122.4.986","volume":"122","author":"G Varela-Moreiras","year":"1992","unstructured":"Varela-Moreiras G, Selhub J (1992) Long-term folate deficiency alters folate content and distribution differentially in rat tissues. J Nutr 122:986\u2013991","journal-title":"J Nutr"},{"key":"2094_CR33","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1021\/jm201688n","volume":"55","author":"L Wang","year":"2012","unstructured":"Wang L, Cherian C, Kugel Desmoulin S, Mitchell-Ryan S, Hou Z, Matherly LH, Gangjee A (2012) Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. J Med Chem 55:1758\u20131770","journal-title":"J Med Chem"},{"key":"2094_CR34","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/jm9015729","volume":"53","author":"L Wang","year":"2010","unstructured":"Wang L, Cherian C, Kugel Desmoulin S, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly LH, Gangjee A (2010) Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. J Med Chem 53:1306\u20131318","journal-title":"J Med Chem"},{"key":"2094_CR35","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1021\/jm200739e","volume":"54","author":"L Wang","year":"2011","unstructured":"Wang L, Kugel Desmoulin S, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang MH, Mitchell-Ryan S, Stout M, Romero MF, Hou Z, Matherly LH, Gangjee A (2011) Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits beta-glycinamide ribonucleotide formyltransferase. J Med Chem 54:7150\u20137164","journal-title":"J Med Chem"},{"key":"2094_CR36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0167-8140(84)80077-8","volume":"2","author":"JL Wike-Hooley","year":"1984","unstructured":"Wike-Hooley JL, Haveman J, Reinhold HS (1984) The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 2:343\u2013366","journal-title":"Radiother Oncol"},{"key":"2094_CR37","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1158\/1078-0432.CCR-1066-03","volume":"10","author":"R Zhao","year":"2004","unstructured":"Zhao R, Gao F, Hanscom M, Goldman ID (2004) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718\u2013727","journal-title":"Clin Cancer Res"},{"key":"2094_CR38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10555-007-9047-1","volume":"26","author":"R Zhao","year":"2007","unstructured":"Zhao R, Goldman ID (2007) The molecular identity and characterization of a proton-coupled folate transporter\u2014PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev 26:129\u2013139","journal-title":"Cancer Metastasis Rev"},{"key":"2094_CR39","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/S1462399409000969","volume":"11","author":"R Zhao","year":"2009","unstructured":"Zhao R, Matherly LH, Goldman ID (2009) Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11:e4","journal-title":"Expert Rev Mol Med"},{"key":"2094_CR40","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1124\/mol.108.045443","volume":"74","author":"R Zhao","year":"2008","unstructured":"Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74:854\u2013862","journal-title":"Mol Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2094-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2094-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T18:24:58Z","timestamp":1644344698000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2094-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,15]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["2094"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2094-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,15]]}}}